All filters
Slidesets
(Abstract) HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression | Dr. L. Colagrossi
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Community perspective | Rebekah Webb
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Roadblocks to implementation | Pep Coll, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
PI remain important options for first line | Linos Vandekerckhove, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Improving PI drug resistance scores | Jens Verheyen, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Breakthrough of preexisting X4-tropic HIV after allogeneic stem-cell transplantation | Dr. J. Verheyen
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Ex vivo determination of stem cell transplantation graft-versus-HIV reservoir effects | Dr. L. Hogan
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Potent Activity of GS-9883, a Novel Unboosted HIV-1 Integrase Strand Transfer Inhibitor (INSTI), Against Patient Isolates with INSTI-Resistance | Dr. K. White
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
HIV in Europe 2020 – what will it look like? | Carlo Federico Perno, MD, PhD
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Dolutegravir plus Rilpivirine in cART-Experienced Subjects: a cohort study | Dr. G. Sterrantino
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Dolutegravir plus Ritonavir-Boosted Darunavir in Highly cART-Experienced Subjects | Dr. G. Sterrantino
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine single tablet regimen | Dr. D. Di Carlo
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
(Abstract) Next generation sequencing in routine HIV-1 resistance diagnostic - frequency of additional resistance relevant mutations in 2% and 1% population | Dr. R. Ehret
Presented at:
European Meeting on HIV & Hepatitis 2016
Slidesets
Selecting the best ART for each patient (English) | Corklin Steinhart, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
Selecting the best ART for each patient (Chinese) | Corklin Steinhart, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
Eradication of HIV (Chinese) | Bonaventura Clotet, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
Eradication of HIV (English) | Bonaventura Clotet, MD, PhD
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
Hepatitis B immunological pathogenesis and immunological assessment | Dr. Chao Wu
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
New Treatments/Targets in HBV (English) | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
New Treatments/Targets in HBV (Chinese) | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
RNAi therapeutics for chronic HBV - Animal models (Chinese) | Dr. Bruce D. Given
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Slidesets
RNAi therapeutics for chronic HBV - Animal models (English) | Dr. Bruce D. Given
Presented at:
Asian Conference on Hepatitis and AIDS (ACHA) 2016